UK MHRA warns against unlicensed Chinese drug

Published: 30-Mar-2010
Ingredients Regulatory

Herbal medicine distributed to 20 traditional Chinese and herbal medicine outlets

More than 900 packs of a potentially dangerous traditional Chinese medicine (TCM) are currently on the UK market despite warnings issued by the Medicines and Healthcare products Regulatory Agency (MHRA).

The unlicensed herbal product Jingzhi Kesou Tan Chuan Wan was distributed to 20 TCM and herbal medicine outlets throughout the UK.

Ekong International (UK) issued a recall in February 2010, however, more than 75% of the stock brought in from China has still not been returned.

The MHRA said new labelling in English had been applied to packs to conceal the original label, which contained the Chinese symbols for Aristolochia, a toxic and carcinogenic plant derivative banned in the UK in 1999.

Exposure to aristolochic acids can result in kidney failure and the development of cancer, particularly of the urinary tract.

MHRA Head of Herbal Policy, Richard Woodfield, said: ‘This is a clear example where natural does not necessarily mean safe. Aristolochia is a highly toxic plant that can cause serious injury and even death if taken.

‘I would strongly advise anyone who has used this product to stop taking it and immediately to consult their doctor.’

See more

You may also like

Regulatory

MHRA approves beremagene geperpavec gene therapy gel for DEB from birth

Read more
The MHRA has approved beremagene geperpavec (Vyjuvek), a topical gene therapy gel for wounds in patients with dystrophic epidermolysis bullosa (DEB), for use from birth onwards

Trending Articles

  1. FDA approves AstraZeneca's FASENRA for hypereosinophilic syndrome AstraZeneca's FASENRA has received FDA approval for hypereosinophilic syndrome in adults and adolescents aged 12 and above, based on Phase III NATRON trial data showing a 65% reduction in the risk of first HES flare compared to placebo
  2. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  3. How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
  5. CARBOGEN AMCIS Shanghai site achieves successful outcome in unannounced NMPA GMP inspection China’s NMPA confirms robust GMP compliance at CARBOGEN AMCIS Shanghai, with no observations identified following an on-site unannounced inspection

Upcoming event

Cleanroom Technology Conference UK

20-21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Regulatory

MHRA approves beremagene geperpavec gene therapy gel for DEB from birth

The MHRA has approved beremagene geperpavec (Vyjuvek), a topical gene therapy gel for wounds in patients with dystrophic epidermolysis bullosa (DEB), for use from birth onwards
Regulatory

MHRA opens Northern Ireland hub in Belfast to bring regulatory expertise closer to local life sciences sector

The new hub, hosted by Invest Northern Ireland in Belfast, will offer local healthcare and life sciences stakeholders direct in-person access to MHRA technical experts on topics including innovation pathways, clinical investigations and regulatory support throughout the product development pipeline
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

MC EXCLUSIVE: MHRA on a mission to redefine UK gene therapy

The UK's medicines regulator is seeking industry input on a landmark overhaul of gene therapy medicinal product definitions — the first substantive update in more than two decades — as synthetic mRNA and CRISPR-based technologies outpace the legal framework designed to govern them
Regulatory

MHRA launches consultation to modernise UK gene therapy medicinal product definitions

The UK regulator is seeking industry feedback on proposed updates to the legal classification of GTMPs, as advances in synthetic biology and gene editing outpace definitions set more than a decade ago
Packaging

Amarox recalls sertraline batch after citalopram blister strips found inside sealed cartons

The MHRA has issued a class two recall of one batch of Amarox's sertraline 100 mg film-coated tablets following a secondary packaging error that resulted in citalopram 40 mg blister strips being included in sealed cartons
Regulatory

MHRA report shows agency met targets and closed year in financial surplus

The UK government agency has reported meeting or exceeding every statutory performance target in the 2025/26 financial year, closing in financial surplus while advancing clinical trials reform and AI regulation
Regulatory

MHRA gives guidance to phase out animal testing

The UK regulatory body is aiming to replace animal usage in science by backing developers using non-animal methods and offering early data reviews, with PETA saying innovation "must be adopted or we will be left in the dust"
Subscribe now